About Oramed Pharmaceuticals (NASDAQ:ORMP)
Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed's flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed's delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company's products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
Industry, Sector and Symbol
Industry MED PRODS
Trailing P/E Ratio-9.11688311688312
Forward P/E Ratio-5.90
Sales & Book Value
Annual Sales$2.46 million
Price / Sales41.01
Price / CashN/A
Book Value$1.44 per share
Price / Book4.88
Return on Equity-49.94%
Return on Assets-25.64%
Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions
What is Oramed Pharmaceuticals' stock symbol?
Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."
How were Oramed Pharmaceuticals' earnings last quarter?
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) posted its quarterly earnings data on Thursday, January, 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.24) by $0.06. The biotechnology company had revenue of $0.61 million for the quarter, compared to the consensus estimate of $0.62 million. Oramed Pharmaceuticals had a negative net margin of 169.17% and a negative return on equity of 49.94%. View Oramed Pharmaceuticals' Earnings History.
When will Oramed Pharmaceuticals make its next earnings announcement?
Where is Oramed Pharmaceuticals' stock going? Where will Oramed Pharmaceuticals' stock price be in 2018?
2 brokers have issued 1-year price objectives for Oramed Pharmaceuticals' shares. Their predictions range from $20.00 to $25.00. On average, they expect Oramed Pharmaceuticals' share price to reach $22.50 in the next year. View Analyst Ratings for Oramed Pharmaceuticals.
Who are some of Oramed Pharmaceuticals' key competitors?
Some companies that are related to Oramed Pharmaceuticals include Sientra (SIEN), Conatus Pharmaceuticals (CNAT), Tandem Diabetes Care (TNDM), NanoString Technologies (NSTG), Nuvectra (NVTR), Trinity Biotech (TRIB), Iradimed (IRMD), SeaSpine (SPNE), Zynex (ZYXI), HTG Molecular Diagnostics (HTGM), Viveve Medical (VIVE), Second Sight Medical Products (EYES), Apollo Endosurgery (APEN), Veru (VERU), Ekso Bionics (EKSO), Vermillion (VRML), ConforMIS (CFMS) and Alphatec (ATEC).
Who are Oramed Pharmaceuticals' key executives?
Oramed Pharmaceuticals' management team includes the folowing people:
- Kevin L. Rakin, Chairman of the Board, Independent Director (Age 57)
- Nadav Kidron, President, Chief Executive Officer, Director (Age 43)
- Hilla Eisenberg, Chief Financial Officer, Treasurer, Secretary
- Joshua Hexter, Chief Operating Officer, Vice President - Business Development (Age 46)
- Miriam Kidron Ph.D., Chief Scientific Officer, Director (Age 76)
- Ronald Edward Law, Chief Strategy Officer (Age 64)
- Aviad Friedman, Independent Director (Age 45)
- Xiaopeng Li, Independent Director (Age 33)
- Leonard Sank, Independent Director (Age 52)
- David Slager, Independent Director (Age 44)
Has Oramed Pharmaceuticals been receiving favorable news coverage?
News coverage about ORMP stock has been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oramed Pharmaceuticals earned a news sentiment score of 0.16 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.26 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Oramed Pharmaceuticals' major shareholders?
Oramed Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.65%) and Millennium Management LLC (0.11%). Company insiders that own Oramed Pharmaceuticals stock include Miriam Kidron, Nadav Kidron and Xiaopeng Li. View Institutional Ownership Trends for Oramed Pharmaceuticals.
Which major investors are buying Oramed Pharmaceuticals stock?
ORMP stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC and Renaissance Technologies LLC. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Nadav Kidron and Xiaopeng Li. View Insider Buying and Selling for Oramed Pharmaceuticals.
How do I buy shares of Oramed Pharmaceuticals?
Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oramed Pharmaceuticals' stock price today?
One share of ORMP stock can currently be purchased for approximately $7.02.
How big of a company is Oramed Pharmaceuticals?
Oramed Pharmaceuticals has a market capitalization of $101.46 million and generates $2.46 million in revenue each year. The biotechnology company earns $-10,480,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis. Oramed Pharmaceuticals employs 14 workers across the globe.
How can I contact Oramed Pharmaceuticals?
Oramed Pharmaceuticals' mailing address is HI-TECH PARK 2/4 GIVAT-RAM PO BOX 39098, JERUSALEM L3, 91390. The biotechnology company can be reached via phone at 011-972-2-566-0001 or via email at [email protected]
MarketBeat Community Rating for Oramed Pharmaceuticals (ORMP)MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Oramed Pharmaceuticals (NASDAQ:ORMP) Earnings History and Estimates Chart
Oramed Pharmaceuticals (NASDAQ ORMP) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/4/2018|| || || || || || || || |
|1/11/2018||Q1 2018||($0.24)||($0.18)||$0.62 million||$0.61 million||View||N/A|
|11/29/2017||Q4 2017||($0.20)||$4.29 million||View||N/A|
|7/6/2017||Q3 2017||($0.27)||($0.15)||$0.61 million||$0.62 million||View||N/A|
|4/5/2017||Q2 2017||($0.19)||($0.24)||$0.60 million||$0.61 million||View||N/A|
|1/11/2017||Q1 2017||($0.20)||$0.61 million||View||N/A|
|11/25/2016||Q4 2016||($0.37)||$0.19 million||($0.93) million||View||N/A|
|7/6/2016||Q3 2016||($0.19)||($0.15)||$0.20 million||$0.16 million||View||N/A|
|4/6/2016||Q2 2016||($0.19)||($0.14)||$0.20 million||$0.13 million||View||N/A|
Oramed Pharmaceuticals (NASDAQ:ORMP) Earnings Estimates
2018 EPS Consensus Estimate: ($1.13)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Oramed Pharmaceuticals (NASDAQ:ORMP)
No dividend announcements for this company have been tracked by MarketBeat.com
Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 2.52%
Oramed Pharmaceuticals (NASDAQ ORMP) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/2/2017||Xiaopeng Li||Director||Buy||89,636||$8.50||$761,906.00||206,350|| |
|4/19/2017||Miriam Kidron||Insider||Sell||52,814||$6.33||$334,312.62|| |
|5/12/2016||Nadav Kidron||CEO||Buy||1,000||$6.95||$6,950.00||957,448|| |
|12/30/2015||Miriam Kidron||CTO||Sell||50,000||$8.90||$445,000.00||142,450|| |
|12/9/2015||Michael Berelowitz||Director||Sell||700||$9.44||$6,608.00||22,896|| |
|12/8/2015||Michael Berelowitz||Director||Sell||1,300||$8.70||$11,310.00||23,596|| |
|3/19/2015||Nadav Kidron||CEO||Buy||2,600||$3.88||$10,088.00|| |
|9/11/2014||Miriam Kidron||CTO||Sell||31,699||$8.41||$266,588.59|| |
|9/10/2014||Miriam Kidron||CTO||Sell||23,000||$8.40||$193,200.00|| |
|9/4/2014||Miriam Kidron||CTO||Sell||8,301||$9.41||$78,112.41|| |
|6/6/2014||Regals Capital Management Lp||Major Shareholder||Buy||2,252||$4.44||$9,998.88|| |
|3/31/2014||Michael Berelowitz||Director||Sell||9,434||$10.50||$99,057.00|| |
|3/25/2014||Regals Capital Management Lp||major shareholder||Buy||75,000||$10.62||$796,500.00|| |
|2/6/2014||Regals Capital Management Lp||major shareholder||Buy||51,292||$15.61||$800,668.12|| |
|7/10/2013||Regals Capital Management Lp||Major Shareholder||Buy||6,630||$7.40||$49,062.00|| |
Oramed Pharmaceuticals (NASDAQ ORMP) News Headlines
|Oramed to Present at Oppenheimer's Annual Healthcare Conference - PR Newswire (press release)|
www.prnewswire.com - March 16 at 8:21 AM
|Oramed to Present at Oppenheimer's Annual Healthcare Conference|
finance.yahoo.com - March 15 at 6:11 PM
|Oramed Adds Two New Members to its Scientific Advisory Board - PR Newswire (press release)|
www.prnewswire.com - March 1 at 8:15 AM
|Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension - PR Newswire (press release)|
www.prnewswire.com - February 22 at 8:22 AM
|Oramed Pharmaceuticals (ORMP) Rating Lowered to Sell at ValuEngine|
www.americanbankingnews.com - February 21 at 12:56 AM
|Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension|
finance.yahoo.com - February 20 at 5:46 PM
|Head-To-Head Survey: SAGE Therapeutics (SAGE) versus Oramed Pharmaceuticals (ORMP)|
www.americanbankingnews.com - February 10 at 12:44 PM
|Oramed Pharmaceuticals (ORMP) Raised to Hold at ValuEngine|
www.americanbankingnews.com - February 8 at 10:02 PM
|Oramed to Present at BIO CEO Investor Conference - PR Newswire (press release)|
www.prnewswire.com - February 8 at 8:11 AM
|Oramed to Present at BIO CEO Investor Conference|
finance.yahoo.com - February 6 at 9:33 AM
|FY2018 EPS Estimates for Oramed Pharmaceuticals, Inc. (ORMP) Lifted by Zacks Investment Research|
www.americanbankingnews.com - February 1 at 12:32 PM
|Oramed Pharmaceuticals' CEO Issues Letter to Shareholders|
www.bizjournals.com - January 19 at 11:48 AM
|Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q1, 2018 By the Numbers : January 19, 2018|
finance.yahoo.com - January 19 at 11:48 AM
|Analysts Issue Forecasts for Oramed Pharmaceuticals, Inc.'s FY2018 Earnings (ORMP)|
www.americanbankingnews.com - January 18 at 2:58 PM
|Blog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular Atrophy|
finance.yahoo.com - January 18 at 11:16 AM
|Oramed Pharmaceuticals (ORMP) Rating Increased to Hold at ValuEngine|
www.americanbankingnews.com - January 1 at 2:20 PM
|Oramed Pharmaceuticals (ORMP) Upgraded by ValuEngine to Hold|
www.americanbankingnews.com - December 23 at 4:14 PM
|Oramed Pharmaceuticals, Inc. (ORMP) Expected to Post Q1 2018 Earnings of ($0.21) Per Share|
www.americanbankingnews.com - December 13 at 10:26 AM
|Oramed Pharmaceuticals' (ORMP) "Buy" Rating Reaffirmed at B. Riley|
www.americanbankingnews.com - December 11 at 10:10 PM
|B.Riley/FBR Resumes Oramed Pharma (ORMP) at Buy - StreetInsider.com|
www.streetinsider.com - December 11 at 4:44 PM
|ValuEngine Lowers Oramed Pharmaceuticals (ORMP) to Sell|
www.americanbankingnews.com - December 5 at 10:12 PM
|Here's Why And How Oramed Pharmaceuticals Is Going After NASH|
www.benzinga.com - November 28 at 4:31 PM
|Oramed Pharmaceuticals' (ORMP) "Buy" Rating Reiterated at HC Wainwright|
www.americanbankingnews.com - November 22 at 8:40 AM
| Brokerages Expect Oramed Pharmaceuticals Inc. (ORMP) Will Post Quarterly Sales of $610,000.00|
www.americanbankingnews.com - November 20 at 10:32 AM
|Reviewing Oramed Pharmaceuticals (ORMP) and Its Peers|
www.americanbankingnews.com - November 19 at 9:26 PM
|Critical Comparison: Oramed Pharmaceuticals (ORMP) and Its Rivals|
www.americanbankingnews.com - November 19 at 3:30 PM
|FDA Nod For AZN's Asthma Drug, Genmab Revises Outlook, NBY Disappoints - Nasdaq|
www.nasdaq.com - November 15 at 7:10 AM
|Oramed Pharma (ORMP) Granted Regulatory Approval to Conduct ... - StreetInsider.com|
www.streetinsider.com - November 15 at 7:10 AM
|Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule|
finance.yahoo.com - November 15 at 7:10 AM
|Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins|
www.streetinsider.com - November 2 at 7:22 AM
|Oramed Pharma (ORMP) Announces Composition of Matter Patent in Europe for Oral Proteins - StreetInsider.com|
www.streetinsider.com - November 1 at 7:18 AM
|Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins|
finance.yahoo.com - November 1 at 7:18 AM
|Oramed Pharmaceuticals Inc. (ORMP) Expected to Post Quarterly Sales of $610,000.00|
www.americanbankingnews.com - October 30 at 4:02 AM
|Oramed to Present at the Diabetes Technology Meeting|
finance.yahoo.com - October 25 at 8:42 AM
|Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by its Scientists|
www.streetinsider.com - October 18 at 1:50 AM
|Oramed Pharma (ORMP) Says Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored ... - StreetInsider.com|
www.streetinsider.com - October 17 at 3:45 PM
|Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists|
finance.yahoo.com - October 17 at 3:45 PM
|Contrasting Oramed Pharmaceuticals (ORMP) & OvaScience (OVAS)|
www.americanbankingnews.com - October 7 at 6:28 PM
|HC Wainwright Reiterates Buy Rating for Oramed Pharmaceuticals Inc. (ORMP)|
www.americanbankingnews.com - October 5 at 3:38 PM
|Oramed to Present at the Disruptive Growth Showcase Conference|
finance.yahoo.com - October 2 at 9:19 PM
|Oramed Now Has a Clear Path to Market With Oral Insulin|
finance.yahoo.com - September 23 at 9:12 AM
|Critical Analysis: Portola Pharmaceuticals (PTLA) versus Oramed Pharmaceuticals (ORMP)|
www.americanbankingnews.com - September 12 at 2:26 AM
|Oramed Pharma (ORMP) Says FDA Meeting Provides BLA Guidance on ORMD-0801|
www.streetinsider.com - September 6 at 7:16 AM
|Oramed Announces Successful Meeting with FDA for Oral Insulin|
finance.yahoo.com - September 6 at 7:16 AM
|Oramed (ORMP): Successful Meeting with FDA for Oral Insulin|
finance.yahoo.com - September 6 at 7:16 AM
|Oramed to Present at the Rodman & Renshaw Global Investment Conference|
finance.yahoo.com - August 30 at 7:40 AM
|Oramed Pharmaceuticals Inc. (ORMP) Expected to Announce Quarterly Sales of $610,000.00|
www.americanbankingnews.com - August 17 at 9:48 AM
|Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Director Purchases $761,906.00 in Stock|
www.americanbankingnews.com - August 3 at 7:52 PM
|Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Expected to Post Quarterly Sales of $610,000.00|
www.americanbankingnews.com - July 29 at 7:21 AM
| Analysts Anticipate Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Announce Earnings of -$0.28 Per Share|
www.americanbankingnews.com - July 27 at 8:10 PM
Oramed Pharmaceuticals (NASDAQ:ORMP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Oramed Pharmaceuticals (NASDAQ:ORMP) Income Statement, Balance Sheet and Cash Flow Statement
Oramed Pharmaceuticals (NASDAQ ORMP) Stock Chart for Monday, March, 19, 2018